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Prevalence of symptoms of vaginal ﬁ stula in 19 sub-Saharan 
Africa countries: a meta-analysis of national household 
survey data
Mathieu Maheu-Giroux, Véronique Filippi, Sékou Samadoulougou, Marcia C Castro, Nathalie Maulet, Nicolas Meda, Fati Kirakoya-Samadoulougou
Summary
Background Vaginal ﬁ stula is a serious medical disorder characterised by an abnormal opening between the vagina 
and the bladder or rectum, which results in continuous leakage of urine or stool. The burden of this disorder in sub-
Saharan Africa is uncertain. We estimated the lifetime and point prevalence of symptoms of vaginal ﬁ stula in this 
region using national household surveys based on self-report of symptoms.
Methods We considered all Demographic and Health Surveys (DHS) and Multiple Indicators Cluster Surveys (MICS) 
from sub-Saharan Africa and included data for women of reproductive age (15–49 years). We estimated lifetime 
prevalence and point prevalence of vaginal ﬁ stula with use of Bayesian hierarchical meta-analysis.
Findings We included 19 surveys in our analysis, including 262 100 respondents. Lifetime prevalence was 3·0 cases 
(95% credible interval 1·3–5·5) per 1000 women of reproductive age. After imputation of missing data, point 
prevalence was 1·0 case (0·3–2·4) per 1000 women of reproductive age. Ethiopia had the largest number of women 
who presently have symptoms of vaginal ﬁ stula.
Interpretation This study is the ﬁ rst to estimate the burden of vaginal ﬁ stula in 19 sub-Saharan Africa countries using 
nationally representative survey data. Point prevalence was slightly lower than previously estimated but these earlier 
estimates are within the prevalence’s credible intervals. Although vaginal ﬁ stula is relatively rare, it is still too common 
in sub-Saharan Africa.
Funding None.
Copyright © Maheu-Giroux et al. Open access article published under the terms of CC BY.
Introduction
Vesicovaginal or rectovaginal ﬁ stula (vaginal ﬁ stula) is a 
serious disorder in which an abnormal opening (ﬁ stula) 
exists between the vagina and the bladder or rectum. 
Vaginal ﬁ stula in resource-poor settings usually results 
from prolonged or obstructed labour (obstetric ﬁ stula), 
but can also be the result of sexual assault or inadvertent 
injuries during surgery, among other reasons. It is a 
highly debilitating condition, with women often 
ostracised because of the resulting constant leakage of 
urine or stool through the vagina.1,2 Eliminating obstetric 
ﬁ stula has been on the agenda of the United Nations 
Population Fund, through its Campaign to End Fistula, 
and the US Agency for International Development 
(USAID) programme for almost a decade.3,4 However, 
quantifying progress through reliable health indicators is 
diﬃ  cult. The burden of vaginal ﬁ stula among women in 
sub-Saharan Africa is largely unknown. The most recent 
community-based estimate of prevalence, using data 
from only two African countries (Ethiopia and The 
Gambia), is 1·60 (95% CI 1·16–2·10) obstetric ﬁ stulas 
per 1000 women of reproductive age.5
Accurate estimates of the number and proportions of 
women with vaginal ﬁ stula are especially diﬃ  cult to 
obtain, as is often the case with indicators of maternal 
morbidity,6 because the disorder is rare and patients face 
discrimination and marginalisation.1,2 In a 2007 review, 
Stanton and colleagues6 described three types of report 
about frequency, incidence, and prevalence of obstetric 
ﬁ stula. The ﬁ rst category is mostly based on personal 
communications that report, without denominators, the 
number of patients treated. This approach was used for 
the Global Fistula Map,7 developed by Direct Relief and 
the Fistula Foundation in partnership with the United 
Nations Population Fund, which maps the worldwide 
treatment capacity for vaginal ﬁ stula and the number of 
corrective surgeries done each year. The second type of 
publication relies on declarations made by the authors, 
or on surgeons’ estimates but the source of data is often 
unclear. The third type, which is least common, describes 
methods and provides appropriate denominators, albeit 
with varying degrees of transparency.
In sub-Saharan Africa, the two main sources of 
standardised nationally representative survey data are the 
Demographic and Health Surveys (DHS), sponsored by 
USAID, and the Multiple Indicators Cluster Survey 
(MICS) sponsored by UNICEF. In 2004, DHS started to 
include questions to estimate the prevalence of vaginal 
ﬁ stula symptoms. However, a standardised vaginal 
ﬁ stula module was introduced only after the 
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recommendations of a 2006 expert meeting. Similarly, 
the fourth round of MICS (2009–11) included a smaller 
but similar module of questions in a small number of 
countries. Some of these survey data have been used to 
describe the scope and magnitude of the problem of 
vaginal ﬁ stula.8–11 However, only recently have a 
suﬃ  ciently large number of standardised surveys been 
done to enable systematic cross-country analysis.
Use of household surveys to estimate prevalence of 
vaginal ﬁ stula, and maternal morbidity generally, is 
challenging.12,13 The survey’s questions are not as accurate 
as the gold standard of a gynaecological examination, 
which could result in overestimated prevalence of such a 
rare disorder.14,15 Sensitivity is not a major concern for 
vaginal ﬁ stula because the disorder is rare, therefore 
prevalence will be overwhelmingly conditioned by the 
survey’s speciﬁ city. However, uncertainty remains about 
the usefulness of self-reported symptoms because the 
DHS vaginal ﬁ stula module has yet to be validated.
We estimated the prevalence of vaginal ﬁ stula, 
adjusting for uncertainty in self-reports, and the 
characteristics of patients from nationally representative 
surveys done in sub-Saharan Africa.
Methods
Data sources
We considered all nationally representative DHS and 
MICS reports with available individual-data records from 
sub-Saharan Africa. We included only surveys with 
questions about “constant leakage of urine or stool 
through vagina” or that incorporated a vaginal ﬁ stula 
module in the questionnaire (appendix). Both DHS and 
MICS are face-to-face household surveys administered to 
women of reproductive age (15–49 years).16 They are 
household surveys that use a multistage sampling 
method to select a nationally representative sample of 
women, excluding homeless and institutionalised 
individuals. The sampling process is generally stratiﬁ ed 
by geographic regions, degree of urbanisation, or both. A 
standard questionnaire is administered by trained staﬀ  
to obtain information on sociodemographic charac-
teristics, health indicators, and, in some countries, self-
reported symptoms of vaginal ﬁ stula.
Procedures
The list of ﬁ stula-related questions varied by survey, but 
for those with a vaginal ﬁ stula module, respondents 
were asked about their knowledge of ﬁ stula, experience 
of ﬁ stula symptoms, presumed cause of their ﬁ stula, 
whether treatment was sought, and the outcome of this 
treatment. Additionally, some of the DHS questionnaires 
and all MICS questionnaires used a contingency 
question about ﬁ stula knowledge before asking about 
experience of ﬁ stula symptoms. Probing questions were 
often used, as well as local terms to describe the 
condition (eg, maladie d’urine in francophone countries; 
appendix). For surveys with a contingency question, we 
have assumed that, if a respondent had never heard of “a 
problem such that [a woman] experience a constant 
leakage of urine or stool from her vagina during the day 
and night”, this respondent had never had symptoms of 
vaginal ﬁ stula.
A few surveys included ﬁ stula questions only for 
women who had had a livebirth in the past 5 years, for 
ever-pregnant women, or for ever-married women. 
Because these surveys used diﬀ erent population 
denominators, they were excluded from our prevalence 
estimates. For countries with more than one survey of 
ﬁ stula symptoms, only the most recent survey was used 
to estimate prevalence.
We assessed two main estimates of prevalence. First, 
we estimated lifetime prevalence of ﬁ stula symptoms. 
This measure is the proportion of respondents who 
reported having ever had symptoms of vaginal ﬁ stula. 
Second, we estimated point prevalence (or present 
prevalence) of ﬁ stula symptoms. One survey explicitly 
asked if women suﬀ ered from such symptoms at the 
time of interview (ie, DR Congo DHS 2007), whereas 
others collected information for women who sought 
treatment for vaginal ﬁ stula and the outcome of such 
treatment. Only women who reported a complete 
remission (no more leakage of urine or stool) were 
considered cured and were therefore not  included in the 
numerator of point prevalence.
We estimated the number of women who had ever had 
ﬁ stula symptoms and the number of women who 
presently had vaginal ﬁ stula symptoms for each country 
by multiplying the prevalence estimates by the country-
speciﬁ c number of women of reproductive age according 
to the 2010 population estimates from the UNDP World 
Population Prospects.17
Statistical analysis
We calculated prevalence for each country separately 
with sampling weights provided by DHS and MICS. 
These proportions were then back-transformed to the 
number of women reporting symptoms of vaginal 
ﬁ stula and rounded to the nearest integer. This step 
enabled us to account for the respondents’ diﬀ erent 
probabilities of inclusion in the surveys. Clustering of 
observations for lifetime prevalence of vaginal ﬁ stula 
symptoms could be safely ignored because the 
estimated intraclass correlation coeﬃ  cient18 for this 
rare outcome is very small (0·004) and the average 
number of women surveyed per cluster was also 
small (<30).
We calculated pooled prevalence of vaginal ﬁ stula with 
use of a ﬂ exible hierarchical Bayesian approach, which 
enables sources of variation to be incorporated.19,20 To 
adjust for limitations of the survey instruments, we 
adapted the latent-class model described by Joseph and 
colleagues21 for meta-analysis of prevalence. The model 
assumes that each survey has its own true, but 
unobserved, prevalence and that the survey instruments 
See Online for appendix
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have a common sensitivity and speciﬁ city. The relation 
between these variables is expressed as:
where P₀ is the observed prevalence (as per the survey 
instrument), π is the true unobserved prevalence of the 
disease, Se is the survey instrument’s sensitivity, and Sp 
is the instrument’s speciﬁ city. Because the accuracy of 
the DHS and MICS vaginal ﬁ stula questions has never 
been quantiﬁ ed, the uncertainty related to the sensitivity 
and speciﬁ city of the survey instrument was explicitly 
incorporated into our Bayesian meta-analysis. We used a 
binomial distribution to model the number of women 
reporting vaginal ﬁ stula symptoms (ni). Each survey has 
its own prevalence (πi), considered as a random variable. 
The logit of this variable follows a normal distribution 
with mean υ and SD σ. The complete model speciﬁ cation 
takes the form:
We used a non-informative prior for the mean of the 
logit-transformed individual prevalences (μi). Further-
more, we assumed that the individual survey’s logit-
transformed prevalences were drawn from a normal 
distribution with an SD that had a non-informative 
uniform distribution. We elicited priors for sensitivity 
and speciﬁ city with uniform distributions. We assumed 
that the sensitivity of the survey would most likely be 
95–100% and that speciﬁ city would be 0–99·95%. This 
informative prior entails that we expect a minimum of 
0·5 false positives per 1000 interviewed women. Using 
zero for the lower bound of the uniform distribution for 
speciﬁ city does not aﬀ ect the posterior distribution of the 
prevalence estimate because a rare outcome entails that 
speciﬁ city cannot be lower than 1 minus the observed 
prevalence (appendix).
Among women who reported having ever had vaginal 
ﬁ stula symptoms, we had to impute observations for 
respondents who had missing information about 
whether treatment was sought and the outcome of 
treatment. Furthermore, ﬁ ve surveys recorded infor-
mation about treatment-seeking but not the outcome of 
treatment. For these surveys, we imputed present 
prevalence on the basis of the meta-analysis estimate of 
Figure 1: Lifetime prevalence of vaginal ﬁ stula symptoms per 1000 women of reproductive age in 
sub-Saharan Africa (2005–12)
CrI=credible interval.
Burkina Faso DHS 2010
Senegal DHS 2010−11
Mali DHS 2006
Niger DHS 2012
Congo (Brazzaville) DHS 2011−12
DR Congo DHS 2007
Chad MICS 2010
Togo MICS 2010
Nigeria DHS 2008
Cameroon DHS 2011
Malawi DHS 2010
Tanzania DHS 2010
Guinea DHS 2012
Sierra Leone DHS 2013
Benin DHS 2011−12
Ethiopia DHS 2005
Kenya DHS 2008−09
Comoros DHS 2012
Uganda DHS 2011
Total
20
19
23
19
28
27
45
21
135
63
136
64
59
114
122
111
84
80
171
1341
Women 
reporting
symptoms 
(n)
 0·4 (0·0−1·1)
 0·5 (0·0−1·2)
 0·7 (0·1−1·6)
 0·8 (0·1−1·9)
 1·7 (0·6−2·9)
 1·8 (0·6−3·0)
 1·9 (0·9−3·0)
 2·3 (0·9−4·0)
 3·2 (2·3−4·1)
 3·2 (2·1−4·4)
 5·1 (3·9−6·2)
 5·4 (3·8−7·2)
 5·5 (3·9−7·4)
 6·0 (4·7−7·5)
 6·5 (5·1−8·0)
 7·1 (5·5−8·7)
 9·1 (7·0−11·5)
 14·1 (11·0−17·8)
 19·2 (16·3−22·5)
 3·0 (1·3−5·5)
Prevalence 
(95% CrI)
17 062
15 688
14 580
11 154
10 818
9986
15 857
6375
33 317
15 419
23 010
10 136
9136
16 543
16 599
14 055
8436
5323
8606
262 100
Total 
interviewed
(n)
0 5 10 15 20
Prevalence per 1000 women of reproductive age
Figure 2: Point prevalence of vaginal ﬁ stula symptoms per 1000 women of reproductive age in sub-Saharan 
Africa (2005–12)
*No information recorded about whether treatment for vaginal ﬁ stula was successful; responses were imputed on 
the basis of overall rate of treatment success. CrI=credible interval.
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the proportion of successfully treated women. We 
modiﬁ ed the model to impute these responses by 
explicitly taking into account the associated uncertainty 
(appendix).
We used hierarchical Bayesian meta-analysis to 
estimate self-reported cause of vaginal ﬁ stula symptoms, 
the proportion of respondents who reported vaginal 
ﬁ stula symptoms who sought care, the proportion for 
whom treatment resulted in complete remission, and, 
for women who did not seek care, the reason for not 
seeking treatment. These meta-analyses used the same 
model speciﬁ cation described above, with the diﬀ erence 
that we could not adjust for the imperfect sensitivity and 
speciﬁ city of the case deﬁ nition since these questions 
were contingent on reporting vaginal ﬁ stula symptoms. 
We excluded observations with missing values from 
these analyses.
We ﬁ tted models with Markov chain Monte Carlo 
simulations. We estimated the posterior distributions of 
the parameters of interest with JAGS.22,23 Inferences were 
based on 200 000 iterations (an additional 50 000 iterations 
were used as burn-in). We used the “rjags” library24 to run 
JAGS with R statistical software. We report the median of 
the posterior distribution and its 95% credible intervals 
(CrI) as summary estimates.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
FK-S was responsible for the decision to submit for 
publication.
Results
29 population-based surveys done in sub-Saharan Africa 
included questions about vaginal ﬁ stula (appendix). 
Individual-data records for the following surveys were 
not in the public domain and were therefore excluded 
from our analyses: Equatorial Guinea (DHS 2011), 
Guinea-Bissau (MICS4 2010), and Mauritania (MICS4 
2011). We also excluded Côte d’Ivoire (DHS 2011–12) and 
Malawi (DHS 2004) because the incontinence questions 
were not speciﬁ c—they referred to general incontinence, 
which could result from several other disorders 
(appendix).25 Finally, we excluded Mali (DHS 2012–13) 
because its sample was not nationally representative: 
almost half of the country’s regions were not surveyed 
because of armed conﬂ ict.
Hence, we considered 23 surveys for our analyses. Of 
these, we included 19 surveys in the meta-analysis of 
lifetime prevalence of vaginal ﬁ stula (a total of 
262 100 respondents). We excluded those with diﬀ erent 
Sample size 
(unweighted; n)
Mean age (years)* Illiteracy (%)* Proportion living in 
urban areas (%)*
Mean number of 
children ever born*
Mean age at ﬁ rst 
birth (years)*†
VF Not VF VF Not VF VF Not VF VF Not VF VF Not VF VF Not VF
Benin DHS 2011–12 127 16 472 28·6 28·9 70·4% 72·4% 61·6% 46·3% 2·4 2·7 20·1 20·0
Burkina Faso DHS 2010 20 17 042 33·6 28·8 57·9% 82·8% 42·9% 27·1% 3·3 3·3 19·8 19·0
Cameroon DHS 2011 56 15 363 31·0 27·9 37·6% 40·0% 68·2% 53·8% 3·2 2·7 19·5 18·8
 Chad MICS 2010 40 15 817 29·1 27·8 83·6% 85·8% 45·5% 24·9% 4·1 3·9 12·9 18·4
Comoros DHS 2012 110 5213 30·5 27·6 57·4% 46·2% 51·8% 32·8% 3·1 2·1 20·3 20·6
Congo (Brazzaville) DHS 2011–12 27 10 791 30·0 28·6 25·5% 25·6% 70·8% 68·6% 2·7 2·5 17·5 19·1
DR Congo DHS 2007 44 9942 30·0 28·3 38·7% 51·3% 44·5% 45·4% 4·2 3·0 18·4 19·2
Ethiopia DHS 2005 103 13 952 32·6 28·0 81·5% 78·1% 19·2% 17·7% 4·4 3·1 18·3 18·5
Guinea DHS 2012 63 9073 30·6 28·4 81·6% 79·7% 43·5% 36·3% 3·2 3·0 18·9 18·2
Kenya DHS 2008–09 78 8358 32·6 28·4 36·1% 26·2% 16·0% 25·5% 3·9 2·7 19·0 19·2
Malawi DHS 2010 132 22 878 29·2 28·0 51·1% 40·6% 10·7% 18·7% 3·3 3·1 19·1 18·4
Mali DHS 2006 18 14 562 34·3 28·4 100·0% 88·0% 26·8% 33·7% 5·6 3·6 19·1 18·2
Niger DHS 2006 20 9169 28·4 28·6 95·7% 92·5% 22·2% 19·5% 3·7 4·0 18·0 17·8
Niger DHS 2012 16 11 138 28·7 28·8 100·0% 89·2% 0·0% 18·8% 4·8 4·2 16·9 18·2
Nigeria DHS 2008 142 33 175 30·8 28·7 57·2% 52·5% 30·2% 35·7% 3·6 3·1 19·0 19·4
Rwanda DHS 2005‡ 164 5222 29·1 31·3 52·0% 44·4% 9·9% 14·4% 3·7 4·2 20·7 21·1
Senegal DHS 2010–11 18 15 670 31·7 27·9 72·1% 71·1% 55·2% 49·3% 3·5 2·5 19·4 19·7
Sierra Leone DHS 2013 112 16 431 30·3 28·4 78·9% 68·5% 44·9% 35·4% 3·6 2·9 17·8 18·7
Swaziland MICS 2010‡ 57 3261 34·8 31·7 16·2% 12·3% 19·6% 30·5% 4·0 3·0 29·5 26·5
Tanzania DHS 2010 51 10 085 30·8 28·6 36·1% 33·0% 34·1% 28·5% 2·9 2·9 18·7 19·0
Togo MICS 2010 23 6352 32·9 29·2 78·4% 57·9% 29·3% 45·3% 4·1 2·7 19·0 19·7
Uganda DHS 2006 201 8275 30·8 28·0 60·2% 51·0% 10·7% 17·0% 4·7 3·5 18·1 18·2
Uganda DHS 2011 164 8442 31·0 28·0 51·5% 48·5% 11·4% 19·9% 4·4 3·4 17·9 18·2
VF=ever had vaginal ﬁ stula symptoms. Not VF=never had vaginal ﬁ stula symptoms. DHS=Demographic and Health Survey. MICS=Multiple Indicator Cluster Survey. *Takes into account sampling weights. 
†Excludes women who have never given birth. ‡Have diﬀ erent denominators: women who had a livebirth in preceding 5 years for Rwanda and ever-pregnant women for Swaziland.
Table 1: Characteristics of respondents, stratiﬁ ed by presence of symptoms of vaginal ﬁ stula
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population denominators (Rwanda DHS 2005, and 
Swaziland MICS 2010) and only included the most recent 
survey per country (Niger DHS 2012, and Uganda DHS 
2011). We also included 19 surveys in our estimates of 
point prevalence of vaginal ﬁ stula symptoms: 14 surveys 
had information about present vaginal ﬁ stula symp-
toms or treatment-seeking and treatment outcome 
(141 responses with missing information were imputed) 
and for the ﬁ ve remaining surveys that only recorded 
whether treatment was sought, observations were 
imputed based on overall treatment success 
(229 responses imputed).
Lifetime prevalence of vaginal ﬁ stula was 3·0 cases per 
1000 women of reproductive age (95% CrI 1·3–5·5). 
Prevalence varied between countries, from 0·4 (0·0–1·1) 
in Burkina Faso, to 19·2 (16·3–22·5) in Uganda (ﬁ gure 1). 
Point prevalence of vaginal ﬁ stula symptoms was 
1·0 cases per 1000 women of reproductive age (95% CrI 
0·3–2·4; ﬁ gure 2). Replacing our moderately informative 
prior for speciﬁ city with a completely vague prior that 
uniformly covers the 0–100% range, the estimates 
increase to 3·3 per 1000 women (95% CrI 1·4–5·9) for 
lifetime prevalence and 1·4 per 1000 women (0·4–2·9) for 
point prevalence (appendix). However, the vaginal ﬁ stula 
questions are very unlikely to have had a perfect speciﬁ city 
given that the prevalence of daily post-partum urinary 
incontinence was 3% according to a recent review26 and 
stress urinary incontinence in pregnant women is 
common.27,28 Adjusting for limitations of the survey 
instruments improved prevalence estimates. Assuming a 
perfect sensitivity and speciﬁ city (un corrected estimates), 
lifetime prevalence was 4·4 per 1000 women (95% CrI 
2·9–6·5) and point prevalence was 2·1 per 1000 women 
(1·2–3·3). The diﬀ erence between the corrected and 
uncorrected estimates suggests that many reports of 
vaginal ﬁ stula symptoms could be false positives.
Respondents who reported having ever had vaginal 
ﬁ stula symptoms were slightly older and generally 
reported having had more children than did women who 
did not report such symptoms (table 1). Illiteracy was 
generally more common in women with vaginal ﬁ stula 
symptoms. The associations between reports of vaginal 
ﬁ stula symptoms and living in an urban area and age at 
ﬁ rst birth were highly variable between countries.
We estimated that Uganda and Ethiopia had the largest 
number of women of reproductive age who had ever had 
vaginal ﬁ stula symptoms. Ethiopia also had the largest 
burden of women who presently had symptoms of 
vaginal ﬁ stula (table 2).
Most ﬁ stulas were reported to have resulted from 
pregnancy (71·4%, 95% CrI 59·0–81·4), followed by 
other or unknown causes (14·8%, 6·8–27·3), pelvic 
operations or surgery (4·2%, 2·2–27·3), and sexual 
assaults (3·4%, 6·8–27·3; appendix). Scaling these 
estimates to sum to 1 and after proportional reallocation 
of the other or unknown causes categories, causes of 
ﬁ stulas were most often pregnancy-related (90·4%), 
followed by pelvic operation (5·3%), and sexual assault 
(4·3%). The proportion of ﬁ stulas that resulted from a 
sexual assault was highest in DR Congo (22%).
Among the 19 surveys that recorded whether treatment 
was sought, 70·3% (95% CrI 61·2–78·7) of women who 
had ever had vaginal ﬁ stula symptoms reported having 
sought any treatment (appendix). 13 surveys collected 
information about treatment outcome and 74·7% 
(95% CrI 69·2–79·9) of women who reported having 
sought treatment had a complete remission—deﬁ ned as 
no more leakage of urine or stool (appendix). The reasons 
most often mentioned for not having sought treatment 
were cost (23·8%, 95% CrI 12·9–37·5), not knowing 
where to ﬁ nd treatment (22·3%, 12·0–34·7), not knowing 
the disorder was curable (21·1%, 7·2–33·7), and feeling 
too embarrassed (10·9%, 6·2–17·2; appendix).
Women who did not report having sought care were 
generally younger and of lower socioeconomic status 
than those who had (table 3), although the direction of 
association varied by country.
Discussion
Our meta-analysis of national household surveys from 
sub-Saharan Africa has shown that around three per 
1000 women of reproductive age have had symptoms of 
vaginal ﬁ stula during their lifetime and that roughly one 
per 1000 have such symptoms at present. Ethiopia had 
the largest number of women of reproductive age who 
presently have symptoms, followed by Uganda. To the 
best of our knowledge, this study reports the ﬁ rst 
estimate of the burden of vaginal ﬁ stula in sub-Saharan 
Number of women who have ever 
had symptoms
Number of women who 
presently have symptoms
Benin DHS 2011–12 14 600 (11 500–18 000) 9600 (7300–12 300)
Burkina Faso DHS 2010 1500 (100–4000) 500 (0–2000)
Cameroon DHS 2011 15 500 (10 000–21 400) 1900 (100–5000)
Chad MICS 2010 4900 (2300–7500) 800 (0–2500)
Comoros DHS 2012 2300 (1800–2900) 1200 (900–1700)
Congo (Brazzaville) DHS 2011–12 1600 (600–2800) 100 (0–600)
DR Congo DHS 2007 25 200 (9000–43 100) 14 200 (3600–27 700)
Ethiopia DHS 2005 140 500 (109 700–173 800) 110 800 (85 500–140 100)
Guinea DHS 2012 13 900 (9800–18 700) 8300 (5300–11 900)
Kenya DHS 2008–09 90 100 (69 400–113 700) 49 900 (34 000–69 200)
Malawi DHS 2010 16 900 (13 100–20 900) 5200 (3200–7500)
Mali DHS 2006 23 00 (200–4900) 300 (0–1500)
Niger DHS 2012 2800 (400–6200) 900 (0–3000)
Nigeria DHS 2008 115 200 (82 400–147 700) 46 800 (28 000–67 800)
Senegal DHS 2010–11 1500 (100–3800) 300 (0–1400)
Sierra Leone DHS 2013 8500 (6600–10 600) 4100 (2900–5600)
Tanzania DHS 2010 55 300 (39 400–73 400) 21 400 (10 800–34 700)
Togo MICS 2010 3700 (1400–6300) 1500 (200–3500)
Uganda DHS 2011 142 100 (120 300–166 100) 74 200 (56 000–95 700)
Data are median (95% credible intervals). DHS=Demographic and Health Survey. MICS=Multiple Indicator Cluster Survey.
Table 2: Burden of lifetime and present vaginal ﬁ stula in women of reproductive age (15–49 years) 
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Africa based on recent large national surveys (panel). 
Our estimated point prevalence of symptoms is 
consistent with the number reported by Adler and 
colleagues5 (1·6 cases per 1000 women of reproductive 
age). Another commonly used estimate of prevalence 
comes from the 2000 update of the Global Burden of 
Disease Study. This estimate assumed that 2·15% of 
neglected obstructed labour would result in a vaginal 
ﬁ stula, yielding a prevalence of 1·88 cases per 
1000 women aged 15–44 years in sub-Saharan Africa.29 
Our study shows that prevalence of vaginal ﬁ stula 
estimated from self-reporting is lower (1·0 per 1000) than 
previously reported, but these previous estimates are 
within our credible intervals (0·3–2·4).
Most women with symptoms reported that the cause of 
ﬁ stula was pregnancy. Sexual assaults were not a 
common cause of vaginal ﬁ stula, except in countries that 
have had armed conﬂ icts such as DR Congo,30,31 where 
more than a ﬁ fth of women with symptoms reported 
sexual assault as the cause. Of all women who reported 
having had vaginal ﬁ stula symptoms, more than two-
thirds reported having sought some form of treatment. 
This proportion might include women seeking care 
through traditional healers who can do little when 
modern interventions are needed. Among women who 
sought care, almost three-quarters reported a complete 
remission. This proportion is consistent with previous 
reports, taking into account that several surgeries are 
sometimes needed for complete remission32–34 and that a 
small yet unknown proportion of ﬁ stulas are deemed 
incurable within the challenging health system 
conditions and low resources of sub-Saharan Africa.35,36 
Our results suggest that cost, knowing that eﬀ ective 
surgery exists, and where to go to obtain services are the 
main barriers to treatment.
Our study has some limitations. DHS and MICS have 
constraints in terms of collecting information about a 
sensitive and stigmatising disease.16 Being household-
based, such data could underestimate prevalence if a 
substantial number of women with vaginal ﬁ stula are 
homeless, ostracised by their family,37 or housed in long-
term care facilities dedicated to patients with ﬁ stula.38 
This shortcoming would mostly aﬀ ect our estimates of 
point prevalence. Second, only women of reproductive 
age were interviewed, although women older than age 
50 years and those younger than age 15 years could also 
have vaginal ﬁ stula. Third, we assumed that the surveys 
had common sensitivity and speciﬁ city. This assumption 
was needed to ensure model identiﬁ ability (ie, for the 
model to produce precise inferences). Even if DHS and 
Sample size (unweighted; n) Mean age (years)* Illiteracy (%)* Proportion in bottom 
quintile of SES (%)*
Proportion living in urban 
areas (%)*
Have sought 
treatment
Have not 
sought 
treatment
Have sought 
treatment
Have not 
sought 
treatment
Have sought 
treatment
Have not 
sought 
treatment
Have sought 
treatment
Have not 
sought 
treatment
Have sought 
treatment
Have not 
sought 
treatment
Benin DHS 2011–12 56 71 30·0 27·5 71·8% 69·3% 13·0% 10·5% 55·6% 66·5%
Burkina Faso DHS 2010 8 5 33·6 28·1 62·8% 35·4% 11·6% 0·0% 55·9% 52·3%
Cameroon DHS 2011 33 7 31·1 32·5 32·8% 56·6% 1·3% 20·9% 72·4% 57·2%
Chad MICS 2010 32 6 29·6 28·9 81·4% 91·8% 17·7% 23·2% 52·7% 12·5%
Comoros DHS 2012 67 33 30·9 29·4 47·0% 69·3% 12·9% 28·4% 52·7% 53·1%
Congo (Brazzaville) DHS 2011–12 19 2 30·4 26·8 22·2% 0·0% 10·9% 55·0% 80·7% 45·0%
DR Congo DHS 2007 31 12 28·6 31·7 38·1% 55·7% 13·5% 12·4% 46·8% 58·1%
Ethiopia DHS 2005 33 67 36·1 31·2 86·8% 80·1% 18·3% 23·3% 29·1% 13·8%
Guinea DHS 2012 37 24 30·8 30·5 85·2% 74·0% 13·8% 47·8% 47·1% 33·8%
Kenya DHS 2008-09 47 31 35·6 28·6 35·8% 36·4% 10·9% 13·0% 19·3% 11·6%
Malawi DHS 2010 108 24 29·9 25·4 53·1% 39·0% 25·1% 17·9% 11·0% 8·5%
Mali DHS 2006 16 2 35·0 30·9 100·0% 100·0% 26·6% 100·0% 32·4% 0·0%
Niger DHS 2006 4 3 28·5 30·0 100·0% 100·0% 32·8% 66·7% 7·1% 0·0%
Niger DHS 2012 15 1 28·0 35·0 100·0% 100·0% 19·2% 0·0% 0·0% 0·0%
Nigeria DHS 2008 62 23 30·6 31·6 70·6% 57·4% 34·2% 18·2% 25·2% 28·5%
Rwanda DHS 2005† 57 106 28·1 29·7 51·3% 52·8% 10·4% 25·6% 12·0% 8·8%
Senegal DHS 2010–11 12 6 30·7 35·6 68·3% 86·0% 26·4% 50·9% 60·4% 35·8%
Sierra Leone DHS 2013 68 35 31·0 28·6 76·9% 85·6% 14·1% 22·7% 46·8% 38·2%
Tanzania DHS 2010 18 6 33·1 26·5 31·5% 64·2% 21·9% 24·7% 24·7% 37·6%
Togo MICS 2010 14 9 34·1 31·2 76·5% 81·2% 5·4% 40·6% 36·4% 18·8%
Uganda DHS 2011 98 66 32·1 29·1 56·7% 42·8% 18·0% 18·5% 13·3% 8·3%
DHS=Demographic and Health Survey. MICS=Multiple Indicator Cluster Survey. SES=socioeconomic status. *Takes into account sampling weights. †Has a diﬀ erent denominator: women with a livebirth in 
preceding 5 years.
Table 3: Characteristics of women reporting vaginal ﬁ stulas symptoms, stratiﬁ ed by care
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MICS used a standardised method, we cannot rule out 
that the quality of a questionnaire’s translation into local 
languages could have resulted in diﬀ erent sensitivity or 
speciﬁ city for the vaginal ﬁ stula questions. Furthermore, 
the respondents’ understanding of the question and 
familiarity with vaginal ﬁ stula could have varied between 
region and country. This eﬀ ect could partly explain why 
prevalence in Uganda was many times higher than that 
in the other countries, despite our adjustments. However, 
exclusion of this survey from the meta-analyses had only 
a minor eﬀ ect on our overall summary measures, with 
estimates of 2·8 (95% CrI 1·2–4·9) per 1000 women for 
lifetime prevalence and 0·9 (0·2–2·1) per 1000 for point 
prevalence.
Fourth, our CrIs were not adjusted for the complex 
survey design, which could underestimate the sampling 
variance. Nonetheless, use of the design-based 
adjustment of Korn and Graubard,39 which substitutes 
the original sample size for an eﬀ ective sample size 
adjusted for the correct number of degrees of freedom, 
had little eﬀ ect on the width of the CrI for lifetime 
prevalence (this adjustment could not be done for point 
prevalence because of the imputation of missing 
observations; data not shown). Finally, survey data 
provide lifetime and not lifecourse information. Proﬁ le 
diﬀ erences between women who reported vaginal 
ﬁ stula symptoms and those who did not, as well as 
those who did and did not seek treatment, should be 
interpreted with caution. For example, the high 
proportion of women reporting vaginal ﬁ stula who, in 
certain countries, live in urban areas could have resulted 
from migration caused by greater accessibility to 
treatment services in urban centres. Additionally, these 
descriptions are limited by the fact that the case 
deﬁ nition probably includes a high proportion of false 
positives.
This study also has strengths. First, our prevalence 
estimates are based on 19 nationally representative 
surveys and responses were pooled. As such, we have 
improved on earlier estimates by greatly expanding the 
number of countries represented. We also incorporated 
uncertainty about the accuracy of the questions about 
vaginal ﬁ stula, as well as uncertainty in the imputation of 
missing observations for point prevalence through a 
cohesive Bayesian approach.
Our ﬁ ndings show that the point prevalence of vaginal 
ﬁ stula is slightly lower than previously reported. This 
diﬀ erence could have resulted from continued 
improvements of maternal health in sub-Saharan Africa 
over the past decade40,41 and the increased availability of 
and accessibility to corrective surgery.42,43 Despite the high 
uncertainty of our estimates, we have shown that national 
household surveys based on self-report of symptoms can 
be used to estimate disease burden. In view of the 
potentially high rate of false positives, estimates from 
self-reported vaginal ﬁ stula symptoms should be adjusted 
for the imperfect speciﬁ city of the questionnaires. 
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Panel: Research in context
Systematic review
Vaginal ﬁ stula aﬀ ects the health and lives of many women in 
the most deprived parts of the world. As an issue of public 
health and reproductive health rights, it embodies many of 
the challenges faced by the post-2015 maternal health 
agenda in sub-Saharan Africa (how to ensure timely access to 
emergency obstetric care, address the shortages of skilled 
human resources, improve quality of care within low-
resource health systems, and maintain the rights of women 
to reproductive health care during their whole life). Over the 
past decade, an international campaign has boosted ﬁ stula 
prevention, treatment, and research. Yet, the planning and 
evaluation of ﬁ stula interventions have been hampered by 
the lack of reliable prevalence estimates. A systematic review5 
identiﬁ ed only two robust population-based studies of the 
prevalence or incidence of vaginal ﬁ stula in Africa. We 
searched PubMed, Web of Knowledge, and Google Scholar 
with the term “(“obstetric ﬁ stula” OR “vesico-vaginal ﬁ stula” 
OR “vesicovaginal ﬁ stula” OR “recto-vaginal ﬁ stula” OR 
“rectovaginal ﬁ stula” OR “genito-urinary ﬁ stula” OR 
“genitourinary ﬁ stula”) AND (“prevalence” OR “incidence”)”. 
This search conﬁ rmed the lack of population-based estimates 
of ﬁ stula burden in Africa. Adler and colleagues5 had rejected 
all studies based on self-reports of ﬁ stula because of concerns 
about the accuracy of maternal morbidity questionnaires. 
Taking these concerns into account, we used a Bayesian 
approach to estimate the pooled prevalence from the 
Demographic and Health Surveys and the Multiple Indicator 
Cluster Surveys, which enabled us to incorporate uncertainty 
about the surveys’ accuracy.
Interpretation
The lifetime prevalence of vaginal ﬁ stula symptoms in sub-
Saharan Africa was 3·0 (95% CrI 1·3–5·5) per 1000 women of 
childbearing age and the point prevalence was 1·0 (0·3–2·4) 
per 1000 women. Ethiopia had the largest number of women 
who presently have symptoms, followed by Uganda. The 
prevalence of vaginal fistula according to self-report was 
lower than previously reported, but previous estimates are 
with the credible intervals. We have improved on earlier 
estimates by including many more countries. However, our 
results should be interpreted with caution because of the 
potential limitations of surveying a rare and ostracising 
disorder such as fistula. Although vaginal fistula is rare, it 
remains too common in sub-Saharan Africa.
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